Omecamtiv Mercabil: unaussprechlich, aber ausgesprochen gut?

Omecamtiv mercabil: unpronounceable but pronouncedly good?

Der Kardiologe (2021)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

US$ 39.95

Tax calculation will be finalised during checkout.

Literatur

  1. 1.

    Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E (2019) Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 380(6):539–548

    CAS  Article  Google Scholar 

  2. 2.

    McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995–2008

    CAS  Article  Google Scholar 

  3. 3.

    McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004

    Article  Google Scholar 

  4. 4.

    Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. Lancet 396(10254):819–829. https://doi.org/10.1016/S0140-6736(20)31824-9

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Cardioangiologisches Centrum Bethanien (CCB), Frankfurt, Deutschland

    Prof. Dr. Holger Eggebrecht

Authors
  1. Prof. Dr. Holger Eggebrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Prof. Dr. Holger Eggebrecht.

Ethics declarations

Interessenkonflikt

H. Eggebrecht gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Eggebrecht, H. Omecamtiv Mercabil: unaussprechlich, aber ausgesprochen gut?. Kardiologe (2021). https://doi.org/10.1007/s12181-021-00451-2

Download citation